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Animal models of cystic fibrosis, in particular several different mutant mouse strains obtained by homologous recombination, have
contributed considerably to our understanding of CF pathology. In this review, we describe and compare the main phenotypic features of
these models. Recent and possible future developments in this field are discussed.
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1. Introduction website of the European Working Group CFTR ExpressionAs described elsewhere in this issue [Bals, 2004; Wil-
lems, 2004;Ulrich, 2004; Davidson, 2004], epithelial cells in
culture allow us to perform many important studies in the
field of CF. Yet, despite progress recently made, these
models lack the specific differentiation pattern, and struc-
tural complexity of intact organs. Therefore, animal models
are still essential in the study CF pathogenesis, and in the
evaluation of novel therapeutic strategies.
A comprehensive review of all available literature on this
subject, more than 2500 monographs at the latest count, is
beyond the scope of this paper. To give the reader access to
this field, we will highlight several available animal models
that have been used frequently in CF research, and point out
relevant forthcoming developments. For further information
on handling, acquiring and using the models, we refer to the1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.05.039
Abbreviations: AML, amiloride; Bc, Burkholderia cepacia; BMT,
bumetanide; Ca-ion, Ca2+-ionophore ionomycin; DIDS, 4,4V-diisothiocya-
natostilbene-2,2V-disulfonic acid; ENaC, epithelial sodium channel; FABP,
fatty-acid-binding protein; FSK, forskolin; Hi, Haemophilus influenzae;
iNOS, intracellular nitric oxide syntethase; KO, knockout; LPS, lipopoly-
saccharide; MCC, mucociliary clearance; Pa, Pseudomonas aeruginosa;
PCL, periciliary liquid layer; RSV, respiratory syncytial virus; Sa,
Staphylococcus aureus.
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The cloning of the CF gene in 1989 [1] boosted CF
research. One of the novel approaches that emerged from
this breakthrough was the generation of mouse strains with
a mutation of the mouse Cftr gene. This could be done
with a technique pioneered by Thomas and Capecchi [2],
which uses homologous recombination in mouse embry-
onic stem cells to target a mutation to a specific site in the
mouse genome. The resultant mutant embryonic stem cells
are injected into blastocysts, to produce first chimeric
mice, and subsequently a mutant strain through germ-line
transmission of the mutant allele. Several groups have
independently produced CF mutant mouse strains in this
way. A list of currently available CF mouse models made
by homologous recombination is shown in a table which is
available in hyperlinked form at the above-mentioned
website [81].3. Knockout and residual function mouse models of CF
The initial mouse models of CF were created with
mutations that resulted in a complete loss of function, usinged by Elsevier B.V. All rights reserved.
B.J. Scholte et al. / Journal of Cystic Fibrosis 3 (2004) 183–190184a ‘‘replacement strategy’’ to produce an interruption of the
Cftr gene. Examples of these are the mutants generated by
the North Carolina (Cftrtm1Unc) [3], Cambridge (Cftrtm1Cam)
[4], Toronto (Cftrtm1Hsc) [5] and Baylor (Cftrtm3Bay) [6]
groups. These do not produce detectable amounts of Cftr
mRNA and are considered complete loss of function
(‘‘knockout’’, KO) mutations. In addition, models using
an ‘‘insertional strategy’’ were described by the Edinburgh
(Cftrtm1Hgu) [7] and Baylor (Cftrtm1Bay) [8] groups that
produce low levels of normal mouse Cftr mRNA, despite
interruption of the Cftr gene. These have been described as
‘‘residual function’’ models. In each model, mutant animals
could be determined on the basis of their bioelectric
phenotype, with these analyses revealing classical charac-
teristics of CF in humans (reviewed in Refs. [9,10]).
However, differences in bioelectric, and other phenotypes
were apparent between the models, some of which could be
attributed to their specific mutation. Thus, while these
earlier mouse models have been fundamental to subsequent
research in this field, it could not be assumed that the
laboratory mutations would accurately replicate the effects
of specific clinical mutations, in which dysfunctional or
non-functional CFTR protein is produced (such as F508del
and G551D).4. Mouse models with specific CF mutations
To address this concern, another brand of recombinant
CF mouse models was generated with specific clinically
relevant mutations in Cftr. By far, the most common CF
mutation in humans is F508del. This single amino-acid
deletion results in defective intracellular trafficking and
high turnover of the mutant protein. Importantly, it has
been shown that the mutant protein can be functional when
it reaches the plasma membrane. This opens the possibility
to treat CF using a compound that inhibits degradation or
improves trafficking of F508del CFTR. To facilitate these
studies, three groups independently created F508del Cftr
mouse models. Two of these, Cftrtm2Cam [11] and Cftrtm1Kth
[12], were made using an exon 10 replacement strategy
that left a selective marker gene inserted in one of the
introns. This marker gene has an effect on transcription
activity of the mutant allele, but does not affect the protein
product. The third model, Cftrtm1Eur, was made with a ‘‘hit
and run’’ procedure that resulted in a mutant exon only.
Therefore transcription activity of the mutant allele is
identical to the normal allele [13,14]. It has been shown
that the F508del mutation, in the context of the mouse Cftr
sequence, results in a similar, temperature-dependent pro-
cessing defect as the human version [14]. Recent experi-
ments with intestinal mucosa from homozygous Cftrtm1Eur
mice in maintenance culture [15] showed that incubation at
reduced temperature for up to 15 h resulted in wild-type
(wt) levels of CFTR-mediated transepithelial chloride (Cl)
secretion.In addition to these mice, models carrying the human CF
mutations G480C (Cftrtm2Hgu) and G551D (Cftrtm1G551D)
have also been generated, using ‘‘hit and run’’ and ‘‘re-
placement’’ strategies, respectively [16,17]. These also aim
to model relevant human mutations of particular interest.
Similar to F508del CFTR, G480C CFTR has been demon-
strated to be defective in its intracellular processing, and to
show similar channel characteristics to wt protein when
allowed to traffic in Xenopus oocytes. In contrast, G551D
CFTR becomes appropriately localized, but is dysfunctional
as an ion channel. These models also demonstrated charac-
teristic bioelectric profiles (reviewed in Ref. [9]), and certain
mutation-specific phenotypes. Finally, a transgenic KO
model expressing a human CFTR with the G542X mutation
under the control of the intestinal fatty-acid-binding protein
(FABP) gene promoter has been generated and used to study
the effect of aminoglycosides on suppression of this CFTR
premature stop mutation [18].
These mouse models with specific CF mutations provide
a clinically relevant in vivo system to enable the pre-clinical
testing of compounds that emerge from large scale screening
programs and mutation-specific therapeutic approaches.5. Genetic background affects the phenotype of CF
mouse models
Because the most widely used mouse embryonic stem
cell line is derived from 129/Ola mice, and the recipient
blastocysts are preferably from C57/bl6 or FVB mice, all
recombinant mouse models initially were of mixed genetic
background. This is not a major problem with many
experiments, though it may add to experimental variation.
However, experiments aimed at the identification of ‘‘mod-
ifier genes’’, microarray experiments [Galvin, 2004 this
issue] and proteome analysis [Edelman, 2004 this issue]
will depend heavily on the availability of isogenic (‘back-
crossed’) strains. One advantage of mouse models is that
such a comprehensive genetic analysis is possible by a
combination of classical backcross experiments and state-
of-the-art micro-array analysis. Indeed, several groups have
generated inbred CF mutant lines in different genetic
background and observed interesting differences between
resultant strains. By backcrossing experiments, supported
by genetic analysis this pointed to several genetic loci that
modify the CF phenotype in mice [19].
In contrast to CF KO mice, F508del mice show low but
distinct residual CFTR activity in several epithelial tissues,
dependent on the expression level of the mutant Cftr allele.
Interestingly, this is also observed in a sub-population of
F508del CF patients [20]. Presumably, the balance between
inactivation and proper processing of the mutant protein
depends on the genetic repertoire of the individual. Identi-
fication of genes that are associated with residual
DF508CFTR activity could lead to new therapeutic
approaches.
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Mouse models of CF have provided researchers with the
opportunity to start to dissect the pathogenesis of CF, and to
design and test novel therapies, by targeting specific phe-
notypes downstream of Cftr mutation. Although the pheno-
types of the different mouse models of CF bear most of the
same hallmarks, important differences have been observed,
relating to the specific mutation, genetic background, and
environmental factors. As a result, direct comparisons
between the different models must be made with attention
to these modifying influences.
6.1. Intestinal disease
Intestinal disease is the most prominent feature of CF
mutant mice, with symptoms comparable to CF in humans.
Homozygous KO mice are born at Mendelian ratios, but
pups often die with signs of intestinal obstruction both
before and after weaning. Mouse models of CF demonstrate
a wide range of severity in intestinal phenotypes, from
negligible effects on survival in Cftrtm1Eur and Cftrtm2Hgu
mice, to severe intestinal obstruction and 95% mortality in
the Cftrtm1Unc, Cftrtm1Cam and Cftrtm2Cam mice, consistent
with the multi-organ deficiency of an epithelial Cl channel
involved in the regulation of iso-osmotic water transport
(reviewed in Ref. [9]). Interestingly, the Cftrtm1G551D mice
display less severe intestinal disease and consequent mor-
tality than the KO models, in keeping with the effects of this
mutation in humans, in whom a reduced incidence of
meconium ileus is observed [17,21]. Intestinal histology
shows dilated crypts filled with mucous material and goblet
cell hyperplasia, of varying severity. Electrophysiological
analysis, e.g. Ussing chamber experiments [De Jonge, 2004],
confirms the absence of a CFTR dependent Cl current after
stimulation with cyclicAMP agonists, with the exception of
the Cftrtm2Hgu mice. CF mice also generally have reduced
body weight of varying severity. This is probably related to
reduced lipid resorption, in particular fatty acid uptake, in CF
mouse intestine [22]. The molecular mechanism of CF
intestinal disease, in particular the exact relationship be-
tween CFTR deficiency and lipid malabsorption, remains to
be established. We conclude that CF mice provide an
interesting and most likely valid model in this field.
However, this powerful phenotypic manifestation of
murine Cftr mutation presents an obvious difficulty in the
analysis of additional phenotypes. Whereas good survival of
the Cftrtm1Eur, Cftrtm2Hgu and Cftrtm1Hgu allowed longer-term
studies, the high mortality of other models required alter-
native solutions to be found. Death around the time of
weaning appears to result from the consumption of solid
food, and the use of a liquid diet has been shown to prolong
the lifespan of Cftrtm1Unc mice [23]. However, observations
on mice weaned using these diets suggest care must be taken
that subsequent phenotypic observations are not simply a
result of malnutrition [24]. An alternative approach utilisedthe expression of human CFTR cDNA in the intestinal tract
of Cftrtm1Unc mice, under the control of the rat intestinal
FABP gene promoter. These Cftrtm1Unc-TgN(FABPCFTR) mice
demonstrated decreased lethality from the intestinal defect
in the mutant mice and a longer survival, despite inappro-
priate cell-specific expression [25], and has enabled longer-
term studies of mice bearing this mutation.
6.2. Pancreatic disease
Pancreatic insufficiency is a is a major problem in many
CF patients, but it has not been convincingly demonstrated
in most mouse models of CF. In one study, Cftrtm1Unc mice
weaned on a liquid diet demonstrated significant differences
in pancreatic growth and specific enzyme activities [24].
However, controls showed similar, albeit less severe, abnor-
malities on this diet in comparison with solid diet fed mice.
A further study in Cftrtm1Unc mice, also using a liquid
elemental diet, reported luminal dilatation and the accumu-
lation of zymogen granules at the apical pole of the ductal
epithelial cells [26]. This phenotype has since been used,
and corrected, in a study of the role of dietary fatty acids in
CF [27] The less severe nature of pancreatic disease in
mouse model of CF appears to be the result of lower levels
of expression of Cftr in the murine pancreas and the
presence of an alternative fluid secretory pathway, which
is activated by increases in intracellular calcium [28]. This
indicates that other ion channels might be capable of
compensating for the loss of CFTR and suggests novel
therapeutic approaches in humans, to identify and utilize
such pathways.
6.3. Lung disease
The most significant impact of CF in affected individuals
is progressive pulmonary disease, which causes 95% of the
morbidity and mortality. This lung disease is not evident at
birth, but develops over repeated acute exacerbations of
pulmonary infections with a characteristic spectrum of
pathogens (including respiratory syncytial virus (RSV),
Staphylococcus aureus (Sa), Haemophilus influenzae (Hi),
Pseudomonas aeruginosa (Pa) and Burkholderia cepacia
(Bc)), chronic microbial colonisation, tissue damaging in-
flammation, and irreversible deterioration of lung function
[29–31]. Chronic pulmonary infection with Pa is the
primary concern, with the characteristic transition of this
organism to mucoid phenotype clearly correlated with poor
prognosis and clinical decline [32]. However, it remains
unclear whether CFTR dysfunction results directly in an
increased predisposition to infection with this organism, or a
broader susceptibility resulting in repeated infection with
organisms such as Sa and inappropriate inflammatory
responses generating a lung environment that favours sub-
sequent infection with Pa. This distinction is of clear
importance in designing novel therapeutic approaches, but
remains difficult to resolve in clinical studies. The develop-
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to assist in dissecting the pathogenesis of CF lung disease
and a number of lung models have been described. How-
ever, despite various unequivocal bioelectric phenotypes,
developing an appropriate patho-physiological model of
infectious and inflammatory lung disease in CF mice has
proved challenging.
6.4. Bioelectric phenotype of murine CF airways
The hyperactivity of the amiloride (AML)-sensitive ep-
ithelial sodium (Na+) channel, ENaC, a prominent feature of
CF in human nasal and bronchial epithelium and exploited
as a prime diagnostic criterion [33,34] is faithfully repro-
duced in nasal epithelium from CF mice, irrespective of the
genetic background or specific mutation (Fig. 1A)
[10,35,36]. In this tissue, CFTR immunoreactivity is con-
fined mainly to the microvilli of the olfactory supporting
cells (brush cells; [37]) where it is co-localized with ENaC
[38], presumably facilitating their functional interaction.
The importance of ENaC as a major determinant of Na+
and fluid absorption in the airways and a regulator of the
periciliary liquid layer (PCL) height and mucociliary clear-
ance (MCC) has been illustrated recently in transgenic
mouse models in which overexpression of the h-subunit
of ENaC results in a significant reduction in PCL height and
MCC, mucus retention, goblet cell metaplasia and severe
mucus plugging, causing asphyxia and death [39].
Interestingly, the defect in cAMP-activated Cl secre-
tion, a hallmark of CF in human airway epithelium, could
be demonstrated at the level of nasal [10,35,36] and tracheal
[40] epithelium in some CF mouse models but not in others
(Fig. 1B). The forskolin (FSK)-activated Cl current that
we observed in our homozygous F508del Cftrtm1Eu mice
(FVB/129 and FVB congenics) and in the Cftrtm1Cam-null
mice (C57Bl/6/129 background) appeared to be 4,4V-diiso-
thiocyanatostilbene-2,2’-disulfonic acid (DIDS)-insensitive
and could not be reproduced by calcium-linked agonists
(e.g., Ca2 +-ionophore; thapsigargin; ATP; UTP; Fig. 1B
and data not shown), arguing against a role of cAMP-
provoked (dependent?) Ca2 + signaling in the Cl secretory
response. These and other data (not shown) suggest that
some, but not all strains of CF mice, dependent on their
genetic background and environment, are able to express a
‘‘pseudo-CFTR’’ Cl channel in their airways, which is
cAMP-sensitive and differs from a Ca2 +-regulated Cl
conductance. The elucidation of the molecular identity of
this non-CFTR channel and a more detailed knowledge of
its mechanism of activation and induction may suggest
novel approaches to antagonize the Cl secretory defect in
CF airways and to reduce surface liquid volume depletion.
6.5. Pathophysiological changes in murine CF airways
Initial characterisation of the different CF mice demon-
strated no gross lung disease, suggesting that CF pulmonarypathology might not be effectively modelled without expo-
sure to pathogens. Although this may be largely true, a
variety of interesting observations have subsequently been
made in the apparent absence of infection. These include
excessive inflammation observed by histology in Cftrtm1Hgu
mice [41], abnormal MCC in the Cftrtm1Hgu and Cftrtm1Unc
mice [41,42], an increase in goblet cells, with decreased
volume of airway surface liquid in the nasal epithelium of
Cftrtm1Unc mice [43], a more distal extension of submucosal
glands in Cftrtm1Hgu and Cftrtm1G551D mice [44], hypersen-
sitivity of bone marrow-derived macrophages from
Cftrtm1G551D mice to bacterial lipopolysaccharide (LPS)
[45], and abnormalities in intracellular nitric oxide synte-
thase (iNOS) expression in Cftrtm1Unc and Cftrtm1Kth mice
[46,47].
These observations suggest that more subtle pulmonary
phenotypes do indeed occur secondary to Cftr mutation,
which might represent the earliest stages of CF lung disease,
and raise the issue of time scale over which one might
expect the development of severe CF pathology to develop
in a mouse model, or indeed whether it is realistic to expect
the same endpoints in a different species. In addition to
these studies, pulmonary abnormalities have been described
in Cftrtm1Unc mice bred to congenicity on the C57Bl/6 strain
[48], suggesting complex interplay between mutation and
strain type (and thus independently segregating modifier
genes), in addition to the more obvious environmental
influences, such as infectious agents. The range of muta-
tions generated in CF mice, and the potential to exploit
murine strain differences to study genetic modifiers, should
provide powerful opportunities to study these early changes,
in addition to studies of overt infectious models. Indeed,
genetic modifier loci have been identified for submucosal
gland distribution [49] and mononuclear cell interstitial
infiltrate and fibrosis [19] in CF mice.
The first description of abnormal pulmonary responses to
infection came from outbred, mixed background Cftrtm1Hgu
mice exposed to bacteria by aerosolisation. These mice
displayed defective airway clearance of Sa and Bc, and
developed more severe, pathogen-dependent lung pathology
in response to repeated exposure to these pathogens [50].
Another study has also described a similar phenotype of
decreased clearance, with increased pulmonary pathology,
in response to repeated exposure to Bc in Cftrtm1Unc mice
[51]. The observation of more severe pathology in response
to a CF clinical isolate of the most frequent early CF lung
pathogen Sa has more recently been replicated in Cftrtm1Hgu
mice and Cftrtm1Hgu/Cftrtm1Unc compound heterozygote
mice bred to congenicity on the C57Bl/6 strain, confirming
this enhanced susceptibility [52]. The failure of CftrHgu/
Cftrtm1Unc compound heterozygote mice to develop a more
severe phenotype than the ‘‘residual function’’ Cftrtm1Hgu
homozygote mice indicates that a decrease in residual wt
Cftr mRNA from approximately 10% to 5% of normal
levels does not exacerbate this lung phenotype. This sug-
gests that the lung may be very sensitive to loss of
Fig. 1. (A) Na+ hyperabsorption in CF mice. Recorded traces of freshly excised nasal epithelium from CFTR-wt (CFTR+/+: FVB/129), mutant (CFTR
F508del/F508del; FVB/129 littermates), and null mice (CFTR / ; C57Bl/6/129). Under short-circuit current conditions, the absorptive AML-sensitive Na+
current is enhanced by 4.7- and 7.3-fold in CFTR mutant and null mice, respectively. Short-circuit current responses to AML were similar in CFTR null mice in
the FVB background (DIsc: 72F 16; n= 5). AML, 10 AM, apical side only. (B) Bioelectrics of Na+ absorption and Cl secretion in nasal epithelium of CF
mice. Short-circuit current (Isc) responses were monitored following serial addition of AML (10 AM, apical; measures AML-sensitive Na+ absorption), the
Ca2 +-ionophore ionomycin (Ca-ion, 5 AM, apical (A) + basolateral (B); measures Ca2 +-activated Cl secretion), the cAMP agonist FSK (10 AM; A+B;
measures cAMP-activated Cl secretion), and bumetanide (BMT 100 AM, B; inhibits Cl secretion by blocking NaKCl2 cotransport at the basolateral
membrane). Data are meansF S.E.M., n= 8–12. For specification of mouse genetic backgrounds, see (A). The large rise in Isc in response to FSK in the CFTR
null mice (not significantly different from wt mice; seen also in the absence of Ca-ion), in contrast to the modest response to Ca-ion, suggests that the FSK-
activated Cl secretion is not due to cAMP-triggered mobilization of intracellular Ca2 + or cAMP-promoted Ca2 + influx.
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normal lung responses to infection, below which further
decreases will have no additional impact. This is consistentwith observations in CF individuals, the vast majority of
who succumb to severe lung infections despite very differ-
ent defects in CFTR transcription, translation or function.
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atic phenotype to establish in mouse models of CF has been
perhaps the most critical: pulmonary infection with Pa.
Initial studies using the Cftrtm1Unc, Cftrtm1Hgu and Cftrtm1Kth
mice found no abnormalities in response to this pathogen
[53–55], significantly contrasting with CF lung disease in
humans. More promising recent studies have demonstrated a
defect in the epithelial cell ingestion of Pa, with greater
bacterial lung burden after 4.5 h in Cftrtm1Kth mice [56], and
Pa oropharyngeal colonisation, with some evidence of
pulmonary spread and mucoid transformation in
Cftrtm1Unc-TgN(FABPCFTR) mice following oral infection
[57]. In addition, following infection with Pa, defective
airway epithelial cell apoptosis, required for pulmonary
clearance of this organism [58], has been demonstrated in
Cftrtm1Kth and Cftrtm1G551D mice [59]. These observations
suggest that careful optimisation may yet enable the devel-
opment of a model of pulmonary infection with motile Pa,
subsequent colonisation, bacterial phenotypic transforma-
tion, and fibrotic lung damage, characteristic of human CF
disease [60]. However, to date, clear evidence of persistent
infection and gross differences in response to Pa have only
been achieved using the agar bead model to mimic chronic
colonisation, both in Cftrtm1Unc mice [61,62] and
Cftrtm1G551D/Cftrtm1G551D mice [63]. These studies use agar
to prevent normal clearance of the bacteria, revealing
phenotype differences in survival and cytokine response,
but less pronounced or no differences with regard to
bacterial proliferation and lung pathology. Although use of
this technique may prove to be effective in the study of the
host response to established infection, by superimposing
bacterial retention on an otherwise unaffected lung, it seems
less likely to provide informative with regard to the initia-
tion and development of early stage lung disease. Indeed, if
predisposition to Pa infection in CF is secondary to previous
cycles of infection with other organisms and subsequent
inflammatory damage, or even the consequent antibacterial
chemotherapy received, difficulty in modelling this infec-
tion in mouse models of CF, reared in sterile conditions,
may not be surprising. It may be that pulmonary exposure to
Pa following, or in conjunction with, repeated exposure to
Sa could prove to be more effective in triggering mouse
lung disease.
Thus in conclusion, despite some tantalising similarities
between CF lung disease in humans and mouse models of
CF, significant differences are evident. The development of
an ideal mouse model of CF lung disease, to enable the
dissection of pathogenesis, or testing of novel therapeutics,
is yet to be achieved. Nevertheless, mouse models of CF
clearly demonstrate a range of abnormal pulmonary pheno-
types as result of the Cftr mutation. It is possible that species
differences such as basic lung physiology and airway
epithelial cellular composition [64], alternative Cl chan-
nels [65] and less widespread submucosal glands in the
murine airways [44], host cationic peptides with different
antibacterial profiles [66,67], or altered specificity or ex-pression of innate pattern recognition receptors [68,69],
might ultimately prevent the generation of such a model.
However, further careful development of phenotypes al-
ready described should at least offer the opportunity to study
relevant elements of the disease pathogenesis secondary to
Cftr dysfunction, even if classical endstage human disease
might not be modelled. Indeed, although the suitability as
endpoints for therapeutic testing remains controversial,
some of the models described above have already been
used as in vivo systems to test novel therapeutic strategies
[70,71].
6.6. Hepatic disease
Gallbladder epithelium in mouse and human expresses
CFTR, and is involved in iso-osmotic water transport.
cAMP-stimulated Cl transport and fluid secretion is absent
in gallbladder of CF KO mice, whereas resorption is normal
[72]. Though direct measurements have not been performed,
it is tempting to hypothesise that a similar condition occurs
in the intrahepatic bile duct epithelium in human CF
patients. This could help to explain bile duct obstruction
and cirrhosis observed in many CF patients [73,74].
6.7. Vas deferens dysfunction
Human CF males generally suffer from infertility caused
by bilateral absence the vas deferens, which contains an-
other ductal epithelium that requires CFTR for proper
function. CF mutant male mice also show severely reduced
fertility. Abnormalities of vas deferens, mucoid obstruction
and luminal collapse, were indeed observed in both
Cftrtm1Eur and Cftrtm1Cam homozygous males [75], but not
the complete absence of the structure, which is characteristic
of human CF males, even in subjects with only mild CFTR
dysfunction [76]. Here too, we observe that CFTR dysfunc-
tion in mice leads to a phenotype comparable to, but not
identical with the human disease, presumably because other
gene products strongly affect its expression.7. Other animal models
CF mutant mouse models clearly have limitations, espe-
cially as a model for CF lung disease. Therefore, other
animals are being studied in the CF field, in particular
sheep, pig and ferret. One important advantage of these
models is that the lung function, size and architecture of
these animals more closely resemble the human situation. In
particular, the role of submucosal glands, which are only
found in the proximal trachea in mice, can be studied in
these models [77,78]. So far, only mice have been success-
fully used in modelling by homologous recombination and
transgenesis. Despite intensive efforts, CF sheep [79] or
ferrets [80] have not been created but may become a
valuable contribution to the field in the future.
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